Strategic company announcements, pipeline updates, financings, leadership changes, and business milestones.
The artificial intelligence landscape in biopharma during 2025 and 2026 is defined by a rapid transition from exploratory pilot programs to massive, industrialized integrations across the drug development lifecycle. The…
The executive landscape of the life sciences sector remains one of the most lucrative in the global economy. As we analyze the Highest-Paid Biopharma CEOs for 2026, it is clear…
The year 2026 marks a pivotal acceleration in the biopharma patent cliff. As multiple blockbuster therapies reach their Loss of Exclusivity (LOE), the industry faces an immediate revenue headwind concentrated…
Executive Summary: As of Q1 2026, the Pharmaceutical Patent Cliff 2026 has entered a “tectonic” phase, with industry estimates projecting that over $200 billion to $275 billion in annual sales…